Company intelligence / Profile preview

Juvenon

Incline Village, Nevada, United States

Ownership: Private
Employees: ~2
Development stage: Other

Overview

Clinical trials of Juvenon's lead product (alpha-lipoic acid + acetyl-L-carnitine) in aging and metabolic conditions have shown small, mixed results in cardiovascular endpoints; no significant effect on oxidative stress markers, but some statistically significant blood pressure lowering in post hoc subgroups. Main product is marketed as a well-tolerated, science-based anti-aging supplement with widespread consumer adoption, rather than a prescription medication

Therapeutic areas: CardiovascularOtherMetabolic Disorders
Modalities: Small moleculeNutraceutical
Industry: Food & Nutrition

Partnerships

Whitaker Cardiovascular Institute (clinical study sponsor)San Francisco State University (study sponsor)

Beyond the preview

Go deeper on Juvenon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Juvenon.

Explore the full profile